NCT03823534 2026-04-22
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
St. Louis University
Phase 3 Recruiting
Clinical Trials
17 trialsNCT06043323 2026-03-12
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03913559 2026-02-12
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT04681105 2026-01-28
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
Phase 1 Completed
NCT02356159 2025-09-30
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00840853 2025-07-09
MULTIPRAT
Baylor College of Medicine
Phase 1 Active not recruiting
NCT03448393 2025-06-04
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04599634 2025-02-04
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT06293586 2024-03-05
Comparison Between Peribulbar And Sub-tenon Blocks on Oculocardiac Reflex (OCR) During Pediatric Strabismus Surgery
Cairo University
Phase NA Unknown
NCT04660799 2023-10-12
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 2 Completed
NCT02999633 2022-03-21
ISLAY
Sanofi
Phase 2 Terminated
NCT00324467 2021-07-22
LYTPET
British Columbia Cancer Agency
Phase 2 Unknown
NCT00185692 2019-12-04
Allogeneic Transplantation From Related Haploidentical Donors
Stanford University
Phase 2 Completed
NCT00482053 2018-05-14
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Stanford University
Phase 2 Terminated
NCT00186628 2017-11-28
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Stanford University
Phase 2 Completed
NCT00923910 2017-04-12
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00490009 2017-03-30
Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
Stanford University
Phase 2 Completed